SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Mining/Resources >

India Globalization Capital Inc (IGC)

IGC RSS Feed
Add IGC Price Alert      Hide Sticky   Hide Intro
Moderator: captainscotty, NetworkNewsWire
Search This Board: 
Last Post: 9/18/2017 3:12:36 PM - Followers: 96 - Board type: Free - Posts Today: 0

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first-mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio

IGC recently exited its legacy businesses and currently holds international investments in land and in a hotel project.

 

Investment Highlights

  • Building a patented portfolio of phytocannabinoid-based pharmaceutical and nutraceutical products for one of the world's fastest growing industries
    Positioning for first-mover advantage by developing novel therapies, applying for patents, and acquiring technologies from related industries
    Strategic alliance with International Pharma Trials provides expertise in the FDA process and pharma-trials

 


Development Pipeline

Through cutting-edge research, IGC is developing a product portfolio of phytocannabinoid-based therapies for the treatment of a wide range of life altering or life threatening indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis.


Target Markets

Attitudes toward cannabis have transformed substantially across the United States. Support for cannabis legalization is rapidly outpacing opposition; 53 percent of Americans believe cannabis should be made legal, compared with 44 percent supporting illegality of cannabis. Within this burgeoning market, IGC has identified key areas to which it can apply its phytocannabinoid-based therapies to address unmet medical needs.

 

Pain

The treatment of pain is a great challenge for health care professionals as it can often debilitate individuals in ways that affect their day-to-day functioning, which significantly impacts the nation's productivity and economy. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion.

A major disadvantage of using currently available drug therapies to treat chronic severe pain is that these opioid based drugs may lead to side effects like hallucinations, constipation, sedation, nausea, respiratory depression, and dysphoria.

IGC-501

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Epilepsy

Approximately 50 million people worldwide are affected by epilepsy (Sanders, 2003), a condition attributed to multiple factors. In dogs and cats, seizures are often caused by abnormal brain activity. They can be subtle or cause violent convulsions. Some seizures only occur once, but repeated seizures require treatment to prevent larger areas of the brain from becoming affected.

IGC-502

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Eating Disorders

Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. Approximately 1.3 million people in the United States are experiencing cachexia associated with cancer, multiple sclerosis, Parkinson's disease, HIV/AIDS, and other progressive illnesses. Notably, cancer-induced anorexia/cachexia is responsible for about 20% of all cancer deaths.

IGC-504 and IGC-506

Indicated for a variety of eating disorders, including cachexia, IGC-504 and IGC 506 are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies. IGC-506 is being developed for both human and veterinary use.

 


Industry Partnerships

IGC has established a strategic alliance with International Pharma Trials, whose doctors and researchers have expertise in disorders of the central and peripheral nervous system as well as expertise in the FDA process and pharma-trials.

The company continues to seek information exchanges with medical cannabis dispensaries, research scientists, doctors, medical and business professionals, and biotech companies working in the cannabinoid space.

Leveraging its business model and collaborative research, IGC can help commercialize products while finding innovative ways of helping patients benefit from cannabinoids.

 


Leadership


Ram Mukunda, President, CEO and Director

Ram Mukunda has served as IGC's executive chairman, chief executive officer, and president since the company's inception on April 29, 2005. From January 1990 to May 2004, Mukunda served as founder, chairman, and chief executive officer of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec was the first pure play international long distance carrier. Mukunda was responsible for organizing, structuring and integrating a number of companies owned by Startec. Under Mukunda's tenure at Startec, the company made an IPO of its equity securities in 1997 on NASDAQ. Prior to Startec, Mr. Mukunda served as Strategic Planning Advisor at Intelsat, a communications satellite services provider.

Mukunda serves as an emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a council member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs.

Mukunda is the recipient of several awards including, the 2013 University of Maryland's International Alumnus of the Year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland.

John Cherin, CFO, Treasurer, PAO

John Cherin is a retired senior executive with international experience in assisting young companies. He has provided insight to top management and Board of Directors on strategic analysis and improvement of operating procedures in financial reporting and operations. From 1966 to 1997, Cherin gained his experience as a senior partner at Arthur Andersen while managing practices aimed at businesses in the US and overseas. In addition he founded and managed Cherin Global Consulting in 1997-2005 and the Cherin Group LLC in 2004 to date. He also served as CFO for IGC in its formative stages for the purpose of raising capital to enable IGC's launch in the post startup phase.

Cherin is a retired CPA, a graduate of Northeastern University class of 1966 and in 1967 was the Silver Medal Recipient from the Massachusetts Society of CPAs.

Claudia Grimaldi, General Manager, Director of Cabaran Ultima

Claudia Grimaldi is the general manager and director of IGC's project development and managing company in Malaysia. Grimaldi is responsible for coordinating the staff in various countries and ensuring timely and accurate regulatory compliance and statutory reporting. Prior to assuming her current role in 2013, she spent three years managing the office of the CEO.

Prior to IGC, Grimaldi worked in human resources and psychotherapy. She graduated Summa Cum Laude from Javeriana University, a top five University in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College. Grimaldi is a member of Delta Mu Delta International Honor Society. She is also fluent in both English and Spanish.

 


India Globalization Capital
PO BOX 60642
Potomac, MD 20859-0642
Phone: (301) 983-0998
www.IGCinc.us

NetworkNewsWire
1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217
www.NetworkNewsWire.com

 

NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
IGC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IGC News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 09/15/2017 05:11:18 PM
IGC News: Statement of Changes in Beneficial Ownership (4) 09/14/2017 03:59:43 PM
IGC News: Alzheimer’s Disease: Cannabis Formulation Shows Promise 09/12/2017 08:45:00 AM
IGC News: Statement of Changes in Beneficial Ownership (4) 08/31/2017 07:09:09 PM
IGC News: Quarterly Report (10-q) 08/18/2017 05:31:20 PM
PostSubject
#5157   IGC Reports Promising Progress of Cannabis-Based Alzheimer’s Drug Candidate NetworkNewsWire 09/18/17 03:12:36 PM
#5156   IGC Provides Update on Data Showing Effectiveness of NetworkNewsWire 09/18/17 09:52:46 AM
#5155   IGC Announces Alzheimer’s Drug Candidate Targeting Aß Proteins NetworkNewsWire 09/12/17 03:02:06 PM
#5154   Alzheimer’s Disease: Cannabis Formulation Shows Promise NetworkNewsWire 09/12/17 08:46:22 AM
#5153   IGC Provides Update on Data Linking THC to NetworkNewsWire 09/11/17 09:15:08 AM
#5152   Every insider in this company is unloading shares Sprycel 09/04/17 02:33:54 PM
#5151   Love the science behind this. CFO with a INTL 09/04/17 11:48:17 AM
#5150   IGC a Dark Horse in the Race to NetworkNewsWire 09/01/17 12:10:53 PM
#5149   IGC Growth Potential Fueled by Phytocannabinoid Treatments NetworkNewsWire 08/31/17 02:38:02 PM
#5148   IGC – The Pros are Already Picking Horses NetworkNewsWire 08/29/17 11:19:14 AM
#5147   IGC's Cannabis-Based Alzheimer’s Disease Treatment Increases Upside Potential NetworkNewsWire 08/22/17 03:24:36 PM
#5146   IGC Focuses on Building Phytocannabinoid-based Pharmaceutical Portfolio NetworkNewsWire 08/21/17 12:10:51 PM
#5145   IGC Reports Financial Results for Quarter Ended June NetworkNewsWire 08/21/17 09:13:14 AM
#5144   IGC Shows Potential for Strong Market Valuation Growth NetworkNewsWire 08/16/17 03:21:00 PM
#5143   IGC – Blockbuster Position for Treating Alzheimer’s NetworkNewsWire 08/04/17 02:23:32 PM
#5142   Potential here! Knowntobe 08/04/17 08:49:32 AM
#5141   IGC Management Quoted in “HIGH TIMES” Article NetworkNewsWire 08/03/17 09:15:11 AM
#5140   IGC Adds Dr. Chuanhai Cao to Medical Research Team NetworkNewsWire 08/01/17 09:06:35 AM
#5138   #IGC: Why are they still in Business? captainscotty 07/25/17 05:06:03 PM
#5137   #IGC: Good News...:-} captainscotty 07/25/17 04:57:46 PM
#5136   #IGC: https://www.otcmarkets.com/stock/IGC/profile captainscotty 07/25/17 04:56:34 PM
#5135   http://www.igcinc.us/ captainscotty 07/25/17 04:51:48 PM
#5133   Potential Blockbuster Treatment for Alzheimer’s Disease Stands Out NetworkNewsWire 07/25/17 08:45:30 AM
#5132   I don't know who that is but thanks stock_clerk 07/22/17 04:22:20 PM
#5130   What's with all the trades- 1 share, 17 stock_clerk 07/22/17 03:57:44 PM
#5129   https://technical420.com/cannabis-article/why-india-globalization-capital-should SBPartners 07/17/17 07:53:13 AM
#5128   IGC Reports Financial Results for Fiscal Year Ended NetworkNewsWire 07/14/17 09:28:27 AM
#5127   IGC's Cannabis Drug Development for Alzheimer’s Backed by NetworkNewsWire 07/13/17 02:08:50 PM
#5126   ?? We recently sat down with Dr. Chuanhai SBPartners 07/03/17 08:15:13 AM
#5125   IGC Featured in Benzinga Article Evaluating Potential of NetworkNewsWire 06/30/17 11:06:51 AM
#5124   RAM A SCAM IS AT IT AGAIN! Sprycel 06/29/17 03:37:07 PM
#5122   RAM A SCAM STRIKES AGAIN!!!! THEY HAVE Sprycel 06/28/17 03:20:32 PM
#5121   IGC at the Threshold of a Potential Alzheimer’s Breakthrough NetworkNewsWire 06/28/17 02:06:19 PM
#5120   IGC was up big yesterday but will the SBPartners 06/27/17 06:54:26 AM
#5119   Possibly the reason, why an austrian pumper has tbhomy 06/27/17 05:05:10 AM
#5118   Backyard therapies ? tbhomy 06/27/17 05:01:50 AM
#5117   Good thing you said something lol VERITAS77 06/26/17 12:05:07 PM
#5116   Going down BigOne30 06/26/17 11:54:39 AM
#5115   .80 Target VERITAS77 06/26/17 11:39:22 AM
#5114   Close the gap! BigOne30 06/26/17 11:19:47 AM
#5113   IGC +33% What a great trader this has become. Love Smilin_B 06/26/17 11:03:17 AM
#5112   .80 VERITAS77 06/26/17 10:36:01 AM
#5111   What a bullshit. Scherf.com the gambler. His arts kondziu 06/25/17 05:24:02 AM
#5110   I agree with your statement. Especially the last Smilin_B 06/19/17 04:09:52 PM
#5108   MUST BE PAYROLL WEEK FOR RAM THE SCAM! Sprycel 06/19/17 03:43:21 PM
#5107   Pharmaceutical Leaders Pave the Way to New Alzheimer’s Treatments NetworkNewsWire 06/15/17 07:00:15 AM
#5106   Dude, im engaging in conversation here. The bold Striker77 06/14/17 12:22:53 PM
#5105   EVERY SINGLE NEWS ANNOUNCEMENT IS LEAD WITH SELLING Sprycel 06/14/17 12:20:58 PM
#5104   In some cases, even if it was a Striker77 06/14/17 12:18:11 PM
#5103   LOL, he has been changing BS stories for Sprycel 06/14/17 12:13:50 PM
PostSubject